About InflammX Therapeutics
InflammX Therapeutics is a company based in Tampa (United States) founded in 2005 by Colin Green. InflammX Therapeutics has raised $28.53 million across 2 funding rounds. InflammX Therapeutics offers products and services including Xiflam™. InflammX Therapeutics operates in a competitive market with competitors including Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
- Headquarter Tampa, United States
- Founders Colin Green
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Inflammx Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$28.53 M (USD)
in 2 rounds
-
Latest Funding Round
$9.13 M (USD), Series B
Jan 12, 2021
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of InflammX Therapeutics
InflammX Therapeutics offers a comprehensive portfolio of products and services, including Xiflam™.
Oral small molecule inhibiting hemichannels for retinal disease treatment
People of InflammX Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of InflammX Therapeutics
InflammX Therapeutics has successfully raised a total of $28.53M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $9.13 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by InflammX Therapeutics
Investment portfolio details for InflammX Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - InflammX Therapeutics
Detailed financials for InflammX Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Inflammx Therapeutics Comparisons
Peer comparison for InflammX Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of InflammX Therapeutics
InflammX Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Provider of cell therapies to treat cancer and hematologic conditions
|
Detailed competitors of InflammX Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Inflammx Therapeutics
Complete news archive for InflammX Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about InflammX Therapeutics
InflammX Therapeutics was founded in 2005 and raised its 1st funding round 7 years after it was founded.
InflammX Therapeutics is headquartered in Tampa, United States. It is registered at Tampa, Florida, United States.
Brian Levy is the current CEO of InflammX Therapeutics.
InflammX Therapeutics is a funded company, having raised a total of $28.53M across 2 funding rounds to date.
InflammX Therapeutics was established in 2005 in Tampa, United States, within the biotechnology sector. Ophthalmic therapeutics are developed, with operations centered on inhibitors targeting inflammasome pathways. Xiflam is provided as an oral NLRP3 inhibitor designed to suppress pathological Cx43 hemichannels and regulate inflammasome activity. Emphasis is directed toward indications such as diabetic macular edema, age-related macular degeneration, and geographic atrophy.
InflammX Therapeutics's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
InflammX Therapeutics offers Xiflam™.